Post Reply
21-40 of 115
BioT will move but then.....Q? is which one move 1st...??.
Since day one. Be realistic, get real and don tink tink the sky will open up with unlimited rescource. take what is on the plate and hope it chenogg...let cee end of d day.
I think it is lucky Biot has something like a benchmark in Epure. BioT could turn corner. What Luck!!!
Hi,
I agreed, that is why Bio-treat now start to move and buy volume is starting to show at 0.7 - 0.705 !
Maybe both could at up at the same price today. Same kind of business but definitle differnet kind of management. If broking house say fair value of Epure is 83c, then i think i should load up on my BioT now.
Hi,
Ha, my prediction is correct, see it is coming down to 0.705 to 0.71, seems it is weak and Bio-treat is creating good respond now ! Good Luck.
Of course I think BioT is better but bcos of the F@###....... management, it has very much dented its credentials.
Hi,
On the other hand, I would rather think Bio-treat is much better as it is a proven track record and not only you hold the stock, a lot of big player still holding. I still think Bio-treat is better than this Epure ! What do you think ?
Cannot beh sai tong, otherwise my BioT bey tong!
Ai ...... "Buoy sai tong at 0.715" now it is breaking down and coming down to 0.71 !
hi,
seems supportn level is staying at 0.715 !
T53, you big investor of Epure arr??
haha so supportive!!!
haha so supportive!!!
IPO px $0.65 lahh.... long into histroy lao.....
Thk. C this and U will know why??
Growth of 20% for FY06. We estimate a CAGR of 35% for net for FY05-07 but
EPS CAGR will be diluted to 17%.
We believe Epure should trade at S$0.83
per share based on 11x CY07, which is a 5% discount to our target valuation
Hi T53, what is the IPO price?
From Gohdirect :
Epure is SGX 4th largest water stock in terms of market capitalization. It
operates in the same market space as Bio-Treat but its net profit is a
third of Bio-Treat?s. Epure has a longer track record and more impressive
portfolio than Bio-Treat. While Bio-Treat has a sexy appeal with its
unique proprietary technology, Epure appears to thrive on effective
customisation. Its outstanding order book at end-Mar 06 implies revenue
growth of 20% for FY06. We estimate a CAGR of 35% for net for FY05-07 but
EPS CAGR will be diluted to 17%. We believe Epure should trade at S$0.83
per share based on 11x CY07, which is a 5% discount to our target valuation
for Sinomem in view of its shorter listing track record.
Yesss...within my expected grey...later U see how...?? is green +ve
Woww really over shadow Centillion and Equation, maybe some help coming later from Chinasky is open up, Cnersave, Synear, C.milk. This grp R from... the same boys...Yahh....
wow starting at $0.7, abt 7.7% of kopi money =)
any one dare to go in now?
Well, at least opened is within my expectation tested $0.70-$0.735cts and i can tell this stock got future to grow with d IFC/World bank , at for the next six mths. SEE see kopi $$$ arrive liao. "beh c yeh"...